This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Trials of interferon beta-1b

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The first trials of interferon in multiple sclerosis used recombinant interferon beta-1b.

Interferon beta-1b differs from the human cytokine in two ways:

  • has an aminoacid substitution at one position
  • is non-glycosylated

Patients treated with the high dose of 8 MIU subcutanesouly on alternate days had the following significant benefits:

  • 34% reduction in the relapse rate
  • marked reduction in disease burden as assessed by T2-weighted MRI imaging after two years

The trials with interferon beta-1b did not show a significant reduction in accumulated disability.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.